BarryRosenbloomMD

PubMed

• 9 citations
  Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
  Barry E Rosenbloom, Maria Domenica Cappellini, Neal J Weinreb, Marta Dragosky, Shoshana Revel-Vilk, Julie L Batista, Davorka Sekulic, Pramod K Mistry> ;American Journal of Hematology. 2022 Oct 1
• 4 citations
  Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.
  Grant Bonesteele, J. Jay Gargus, Emily Curtin, Mabel Tang, Barry E. Rosenbloom, Virginia Kimonis> ;Molecular Genetics and Metabolism Reports. 2020 Dec 1
• 21 citations
  Gaucher disease and SARS-CoV-2 infection: Emerging management challenges.
  Pramod K. Mistry, Manisha Balwani, Deborah Barbouth, T. Andrew Burrow, Edward I. Ginns, Ozlem Goker-Alpan, Gregory A. Grabowski, Reena V. Kartha, Priya S. Kishnani, He...> ;Molecular Genetics and Metabolism. 2020 Jul 1
• 1 citations
  Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
  Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichma...> ;Blood Cells, Molecules & Diseases. 2019 Apr 9
• 11 citations
  MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association
  Neal J. Weinreb, Pramod K. Mistry, Barry E. Rosenbloom, Madhav V. Dhodapkar> ;Blood. 2018 May 31
• 17 citations
  Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
  Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichma...> ;Blood Cells, Molecules & Diseases. 2018 Apr 9
• 25 citations
  Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International ...
  Pramod K. Mistry, Julie L. Batista, Hans C. Andersson, Manisha Balwani, Thomas A. Burrow, Joel Charrow, Paige Kaplan, Aneal Khan, Priya S. Kishnani, Edwin H. Kolodny, ...> ;American Journal of Hematology. 2017 Jul 7
• 46 citations
  Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
  Timothy M. Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas A. Burrow, Ana Maria Martins, Elena Lukina, Barry E. Rosenbloom, Ozlem Goker-Alpan, Nora Wa...> ;Blood. 2017 Apr 27
• 11 citations
  Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE t...
  Rebecca Pleat, Timothy M. Cox, T. Andrew Burrow, Pilar Giraldo, Ozlem Goker-Alpan, Barry E. Rosenbloom, Laura R. Croal, Lisa H. Underhill, Sebastiaan J.M. Gaemers, M. ...> ;Molecular Genetics and Metabolism Reports. 2016 Sep 30
• 32 citations
  Gaucher disease and comorbidities: B-cell malignancy and parkinsonism.
  Timothy M. Cox, Barry E. Rosenbloom, Roger A. Barker> ;American Journal of Hematology. 2015 Jun 22
• 107 citations
  Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferi...
  Timothy M. Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas A. Burrow, Ana Maria Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Ange...> ;Lancet. 2015 Jun 13
• 26 citations
  Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
  Neal J. Weinreb, David N. Finegold, Eleanor Feingold, Zhen Zeng, Barry E. Rosenbloom, Suma P. Shankar, Dominick Amato> ;Orphanet Journal of Rare Diseases. 2015 May 22
• 2 citations
  Bone disease in patients with Gaucher disease.
  Barry E. Rosenbloom, Neal J. Weinreb> ;Expert Review of Endocrinology & Metabolism. 2014 Feb 20
• 18 citations
  A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerabi...
  Gregory M. Pastores, Barry E. Rosenbloom, Neal J. Weinreb, Ozlem Goker-Alpan, Gregory A. Grabowski, Gabriel M. Cohn, David Zahrieh> ;Genetics in Medicine. 2014 May 1
• 99 citations
  Gaucher disease: a comprehensive review.
  Barry E. Rosenbloom, Neal J. Weinreb> ;Critical Reviews in Oncogenesis. 2013 Jan 1
• 83 citations
  Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.
  Pramod K. Mistry, Tamar H. Taddei, Stephan vom Dahl, Barry E. Rosenbloom> ;Critical Reviews in Oncogenesis. 2013 Jan 1
• Preface: Gaucher disease and cancer.
  Barry E. Rosenbloom, Neal J. Weinreb> ;Critical Reviews in Oncogenesis. 2013 Jan 1
• 86 citations
  Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa
  Ans T. van der Ploeg, Richard J. Barohn, Lisa Carlson, Joel Charrow, Paula R. Clemens, Robert J. Hopkin, Priya S. Kishnani, Pascal Laforêt, Claire Morgan, Sharon P. Na...> ;Molecular Genetics and Metabolism. 2012 Nov 1
• 30 citations
  Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4–5 years
  Carla E. M. Hollak, Nadia Belmatoug, J. Alexander Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, Laura van Dussen, Anna Tylki-Szymańska, ...> ;British Journal of Haematology. 2012 Aug 1
• 105 citations
  The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
  Barry E. Rosenbloom, Manisha Balwani, Jeff M. Bronstein, Edwin H. Kolodny, Swati Sathe, A. R. Gwosdow, John S. Taylor, J. Alexander Cole, Ari Zimran, Neal J. Weinreb> ;Blood Cells, Molecules & Diseases. 2011 Jan 15
• 494 citations
  A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
  Ans T. van der Ploeg, Paula R. Clemens, Deyanira Corzo, Diana M. Escolar, Julaine Florence, Geert Jan Groeneveld, Serge Herson, Priya S. Kishnani, Pascal Laforêt, Step...> ;The New England Journal of Medicine. 2010 Apr 15
• 9 citations
  Left Ventricular Thrombus and Embolic Stroke Caused by a Functional Paraganglioma
  Neil A. Buchbinder, Run Yu, Barry E. Rosenbloom, C. T. Sherman, Allan W. Silberman> ;Journal of Clinical Hypertension. 2009 Dec 1
• 11 citations
  Multiple myeloma and Gaucher genes
  Barry E. Rosenbloom, Pamela S. Becker, Neal J. Weinreb> ;Genetics in Medicine. 2009 Feb 1
• 87 citations
  Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal c...
  Katherine B. Sims, Gregory M. Pastores, Neal J. Weinreb, John A. Barranger, Barry E. Rosenbloom, Seymour Packman, Paige Kaplan, Henry J. Mankin, Ramnik J. Xavier, Jenn...> ;Clinical Genetics. 2008 May 1
• 13 citations
  Prevalence of Type 1 Gaucher Disease in the United States
  Neal J. Weinreb, Hans C. Andersson, Maryam Banikazemi, John A. Barranger, Ernest Beutler, Joel Charrow, Gregory A. Grabowski, Carla E. M. Hollak, Paige Kaplan, Henry J...> ;Archives of Internal Medicine. 2008 Feb 11
• Join now to see all

Journal Articles

• Bone disease in patients with Gaucher disease  
  Rosenbloom BE, Weinreb NJ, Expert Rev Endocrin Metab, 1/1/2014
• A multicenter, open-label treatment protocol (HGT GCB 058) of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease: safety and tolerab...  
  Pastores G, Rosenbloom B, Weinreb N, et al, Genet Med, 1/1/2013
• Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism  
  Mistry PK, Taddei T, Vom Dahl S, Rosenbloom BE, Crit Rev Oncog, 1/1/2013
• Gaucher disease: a comprehensive review  
  Rosenbloom BE, Weinreb NJ, Crit Rev Oncog, 1/1/2013
• Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly  
  Weinreb NJ, Rosenbloom BE, Open J Genet, 1/1/2013
• Clinical characteristicws associated with persisting thrombocytopenia in type 1 Gaucher patients treated with imiglucerase for 4 to 5 years  
  Hollak, CEM, Belmatoug N, Cole A, Vom Dahl, S, Deegan P, Goldblatt J, Rosenbloom B van Dussen L, Tylki-Szymanska, Weinreb, N, Zimran, A, Cappellini, MD, Brit J Haematol, 1/1/2012
• Open-label extension study following late-onset treatment study (LOTS) of alglucosidase alfa  
  van der Ploeg, AT, Rosenbloom BE, et al, Molec Genet Metab, 1/1/2012
• A preliminary analysis from the ICGG Gaucher registry: short-term clinical outcomes in Gaucher patients affected by the shortage of imiglucerase  
  Weinreb N, Rosenbloom B, Andersson, H, Cole C, Tripuraneni R, Belmatoug N, Mol Genet Metab, 1/1/2011
• Cardiovascular abnormalities in late-onset Pompe disease an response to enzyme replacement therapy  
  Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK, Rosenbloom BE, et al, Genet Med, 1/1/2011
• The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry  
  Rosenbloom B, Balwani M, Bronstein J, et al, Blood Cells, Mol Dis, 1/1/2011
• A randomized study of Alglucosidase alfa in late onset Pompe disease  
  van der Ploeg AT, Rosenbloom BE, et al, New Engl J Med, 1/1/2010
• Multiple myeloma and Gaucher Genes  
  Rosenbloom BE, Weinreb N, Becker P, Genetics in Medicine, 1/1/2009
• Left ventricular thrombus and embolic stroke caused by a functional paraganglioma  
  Buchbinder NA, Yu r, Rosenbloom BE, Sherman CT, Silberman AW, J Clin Hypertension, 1/1/2009
• Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifectations of type I Gaucher disease: results of a 48-month longitudinal c...  
  Sims, KB, Pastores, GM, Werinreb NJ, Barranger J, Rosenbloom BE, et al, Clin Genet, 1/1/2008
• Prevalence of type 1 Gaucher disease in the United States  
  Weinreb NJ, Andersson HC, Rosenbloom BE, et al, Arch Int Med, 1/11/2007
• Imiglucerase(cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease  
  Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, et al, Clin Genet, 1/1/2007
• Primary hepatic carcinoid presenting with Cushing's syndrome  
  Shah NA, Rosenbloom B, et al, J Endocrinol Invest, 1/1/2007
• The antipoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B-cell chronic lymphoid leukemia  
  Krejci P, Pejchalova K, Rosenbloomc BE, J Leuk Biol, 1/1/2007
• Gaucher disease and cancer incidence: a study from the Gaucher registry  
  Rosenbloom, BE, Weinreb, NJ, Zimran, A, Kacena, KA, Charrow, J, Ward, E, Blood, 1/1/2005
• Individualiztion of long-term enzyme replacement therapy for Gaucher disease  
  Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakesh Cheng A, Rosenbloom, BE, et al, Genet Med, 1/1/2005
• Enzyme replacement therapy and monitoring for children with type I Gaucherdisease: consensus recommendations  
  Charrow J, Andersson HC, Rosenbloom BE, et al, J. Pediat., 1/1/2004
• Gaucher disease type I: revised recommendations on evaluations and monitoring for adult patients  
  Weinreb, NJ, Aggio, MC, Andersson, HC, Rosenbloom, BE, Semin Hemat, 1/1/2004
• Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease  
  Papadakis P, Rosenbloom, BE, Targan S, Gastroenterology, 1/1/2003
• Effectiveness of enzyme replacement therapy in 1, 028 patients with type I Gaucher disease after 2-5 years of treatment: a report from the Gaucher registry  
  Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A, Amer J Med, 1/1/2002
• Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy  
  Santoro D, Rosenbloom BE, Cohen AH, Amer J Kid Dis, 1/1/2002
• Join now to see all

Books/Book Chapters

• Advances in Gaucher disease: Basic and clinical Perspectives 
  Chapter: Gaucher Disease: A Comprehensive Review. 
  Rosebloom, Barry E, Weinreb, Neal JEditors: Grabowski, GA.Future Medicine, London, UK2013
• Online Metabolic and Molecular Basis of Inherited Disease 
  Chapter: Gaucher disease: phenotypic and genetic variation. 
  Grabowski, G, Kolodny, E, Weinreb, N, Rosenbloom B, et al2011
• Hematology, Basic Principles and Practice 
  Chapter: "Hematological problems in patients with cancer and chronic inflammatory disorders" 
  Page 2410 - 2419Weinstein, IM, Rosenbloom, BEChurchill Livingstone, New YorkEdition 3rd,1999
• Hematology: Basic Principles and Practice 
  Chapter: "Hematologic Problems in Patients with Cancer and Chronic Inflammatory Disorders" 
  Page 2144 - 2154Weinstein, I.M., Rosenbloom, B.E.Editors: Furie, B. et. al..Churchill Livingstone, New YorkEdition 2nd,1994
• Altered Glycosylation in Tumor Cells 
  Chapter: The use of myltiple tumor markers to monitor cancer patients. 
  Page 295 - 299Chia, D., Terasaki, P.I., Wiseman, C., Rosenbloom, B.E., Ouwendijk, R., Tokita, K.Alan R. Liss1988
• Ambulatory Care for the House Officer 
  Chapter: "Anemia" 
  Page 172 - 178Rosenbloom, BEEditors: Diamond, NJ, Guze, P.Williams & Wilkens, Baltimore1982
• Join now to see all

Abstracts/Posters

• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Rosenbloom B, et al, World Conference on Lysosomal Storage Disease, 1/1/2015
• Validation study of a DS3 severity score index for adult patients with type 1 Gaucher disease (GD1).
  Weinreb NJ, Finegold D, Feingold E, Rosenbloom B, Shankar S, amato D, World Conf Lysomal Stor Dis, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, Eur Work Grp Gaucher Dis (EWGGD), 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, ASHG, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, SSIEM, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Rosenbloom B, et al, ASH, 1/1/2014
• Stability is maintained in adult patients with Gaucher disease type 1 switched from velaglucerase to eliglustat: a sub-analysis of the eliglustat ENCORE trial.
  Pleat R, Mankowski R, Angell J, Rosenbloom B, World Congress of Lysosomal Storage Diseases, 1/1/2014
• A Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease: safety and tolerab...
  Pastores GM, Rosenbloom B, Weinreb N, et al, COLATEL 2013 Meeting, Buenos Aires, Argentina, 1/1/2013
• Encore: a multi-national, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme re...
  Cox T, Dreclichman G, Cravo R, Balwani M, Rosenbloom B, et al, ICIEM, 1/1/2013
• Encore: a multi-national, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme re...
  Balwani M, Rosenbloom B, et al, Amer Soc Med Genet, 1/1/2013
• ENCORE: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therap...
  Burrows TA, Balwani M, Cox T, Rosenbloom B, et al, Amer Soc Hemat, 1/1/2013
• Multicentre open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy (ERT) for type 1 Gaucher (GD1): safety and tolerability.
  Pastores G, Rosenbloom B, Grabowski G, Weinreb, N, Mardach R, Ibrahim J, Mistry P, Internat Workshop on Lysosomal Strorage Dis, London, UK, 1/2/2012
• Safety of velaglucerase alfa in relation to positive baseline anti-imiglucerase antibody status in type 1 Gaucher disease patients from the treatment protocol HGT-GCB-...
  Pastores GM, Rosenbloom B, Goker-Alpan O, et al, ASHG, 1/1/2012
• Ibrahim J, Pastores GN, Rosenbloom B, et al, ASHG, 1/1/2012
• Safety if velaglucerase alfa in type 1 Gaucher disease patients with anti-imiglucerase antibodies.
  Goker-Alpan O, Pastores G, Rosenbloom B, et al, ASHG, 1/1/2012
• Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease (GD-1): safety and tolerabili...
  Pastores G, Rosenbloom B, Grabowski G, et al, SSIEM, Geneva Switzerland, 1/30/2011
• Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement (ERT) in type 1 Gaucher disease: safety and tolerability.
  Pastores G, Rosenbloom B, Weinreb N, et al, Europ Human Genet Conference, Amsterdam, 1/28/2011
• Multicenter, open-label study of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease (GD1): safety evaluation of the first three infusions fr...
  Pastores G, Rosenbloom B, Weinreb N, et al, Europ Human Genet Conference, Amsterdam, 1/28/2011
• Multicenter, open-label study of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease: 3-month results from the HGT-GCB-058 treatment protocol.
  Pastores GM, Rosenbloom B, Grabowski, G, et al, Amer Coll Med Genet, 1/18/2011
• Thrombocytopenia in the absence of splenomegaly in patients with type 1 Gaucher disease: a preliminary analysis from the ICGG Gaucher Registry.
  Rosenbloom BE, Kulke S, Taylor J, Weinreb NJ, Amer Soc Hematol, 1/11/2011
• Report on the safety of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease and the transition from clinic to home infusions during t...
  Pastores GM, Rosenbloom B, Weinreb N, et al, Amer Soc Hematol, 1/10/2011
• A preliminary analysis from the ICGG Gaucher registry: short-term clinical outcomes in Gaucher patients affected by the shortage of imiglucerase.
  Weinreb N, Rosenbloom B, Andersson H, Belmatoug N, World Conference on LSD's, 1/1/2011
• Safety and tolerability of switching from imiglucerase to velaglucerase alfa in patients with type 1 Gaucher disease.
  Pastores G, Rosenbloom B, Grabowski G, et al, LDN, 1/1/2011
• An analysis from the ICGG Gaucher Registry: a report of Gaucher patients affected by reduced dose of imiglucerase.
  Weinreb N, Rosenbloom B, Andersson H, et al, World Confererence on LSD's, 1/1/2011
• Determinants of persisting thrombocytopenia in patients with type 1 Gaucher disease treated with alglucerase/imiglucerase for 4-5 years.
  Cappellini MD, Rosenbloom B, et al, Eur Soc Hem, 1/1/2011
• Join now to see all

Other

• Ask the Expert. 
  Rosenbloom, BE, Horizons, A Newsletter for the Gaucher Community
  1/1/2008
• Consensus startement by the ICGG (International Cooperative Gaucher Group) U.S. regional coordinators on individualization of enzyme replacement therapy(ERT) for type ... 
  Andersson HC, Charrow J, Kaplan P, Kolodny EH, Mistry PK, Pastores GM, Rosenbloom BE, et al.
• "Meet the Experts: Gaucher diseasae (Diagnosis, Gaucher and Parkinsonism, Gaucher and myeloma, Cerdelga, )" (Teaching Video) 
  Rosenbloom B, Weinreb, N